Holen Sie sich die Stockscreener-App
25.18
1.12%
0.28
Handel nachbörslich:
25.19
0.01
+0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$24.90
Offen:
$24.98
24-Stunden-Volumen:
35.94M
Relative Volume:
0.54
Marktkapitalisierung:
$143.17B
Einnahmen:
$62.79B
Nettoeinkommen (Verlust:
$9.84B
KGV:
14.68
EPS:
1.7156
Netto-Cashflow:
$10.38B
1W Leistung:
+0.36%
1M Leistung:
+0.12%
6M Leistung:
-0.55%
1J Leistung:
-5.37%
1-Tages-Spanne:
$24.83
$25.30
1-Wochen-Bereich:
$24.83
$25.30
52-Wochen-Spanne:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.18 | 141.57B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,080.36 | 961.86B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.35 | 498.60B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.31 | 403.83B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
138.54 | 264.54B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
106.45 | 261.26B | 63.90B | 19.05B | 13.05B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
2 Predictions for Pfizer in 2026 - Finviz
2 Predictions for Pfizer in 2026 - The Motley Fool
Pfizer 2026: The Reset Year (NYSE:PFE) - Seeking Alpha
Pfizer stock rises today as 2026 drug price hikes grab headlines again — what PFE investors are watching - ts2.tech
Pfizer stock slips before the bell as 2026 drug price hikes put PFE back in focus - ts2.tech
Pfizer (PFE) Navigates Patent Losses With Strategic Cost Controls, BMO Capital Reaffirms Outperform Rating - Finviz
Pfizer discloses death in long-term Hympavzi study after thrombotic stroke - The Pharma Letter
Zacks Research Brokers Reduce Earnings Estimates for Pfizer - MarketBeat
Tectonic Advisors LLC Buys 49,737 Shares of Pfizer Inc. $PFE - MarketBeat
New Horizons in Vaccines Market to Boom Worldwide By 2025-2032 - openPR.com
Pfizer Inc.: From Pandemic Icon to Platform Powerhouse - AD HOC NEWS
This Pharma Company’s Gamble Might Finally Be Paying Off - Fortune Herald
Pfizer stock today: PFE slips as report flags 2026 U.S. drug price hikes - ts2.tech
Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30 - FinancialContent
Should You Buy Pfizer While It's Under $30? - The Globe and Mail
Pfizer (NYSE:PFE) Shares Track NYSE Composite Index Session - Kalkine Media
Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes - ts2.tech
Brokers Set Expectations for Pfizer's Q4 Earnings (NYSE:PFE) - MarketBeat
Pfizer stock today: PFE in focus as 2026 U.S. drug price hikes kick off — what to watch next - ts2.tech
Pfizer Inc. $PFE Shares Purchased by Ascent Group LLC - MarketBeat
Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight - ts2.tech
Where Will Pfizer Be in 5 Years? - The Globe and Mail
Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report - Stocktwits
Why Wall Street Gave Up on Pfizer-and Why That May Be a Mistake - Finviz
Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake - MarketBeat
Pfizer stock flat before the bell as report flags 2026 U.S. drug price hikes, including 15% Comirnaty rise - ts2.tech
Pfizer, GSK and other drugmakers eying U.S. price hikes for 350 medicines: report - Seeking Alpha
TD Cowen Sticks to Their Hold Rating for Pfizer (PFE) - The Globe and Mail
Epilepsy Drugs Market Is Booming Worldwide 2025-2032 | Pfizer Inc., Sumitomo Pharma Co., Ltd., Novartis AG - openPR.com
Pfizer Shares Face Mounting Headwinds - AD HOC NEWS
Pfizer Stock Reality Check: Is This Fallen Pandemic King a Secret 2025 Comeback Play? - AD HOC NEWS
Pfizer stock flat after hours as TD Cowen sticks with Hold; Feb. 3 results ahead - ts2.tech
Pfizer (PFE) Braces for Bumpy Years as Growth Pushed Out to 2029 - Finviz
Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook - ts2.tech
Pfizer Completes Early-Stage Acne Trial, Signaling Quiet Expansion in Dermatology - TipRanks
Pfizer Inc. $PFE Shares Acquired by Fort Washington Investment Advisors Inc. OH - MarketBeat
The past three years for Pfizer (NYSE:PFE) investors has not been profitable - Yahoo Finance
Mattson Financial Services LLC Has $665,000 Stock Position in Pfizer Inc. $PFE - MarketBeat
Pfizer stock today: PFE holds near $25 as year-end trading turns to Fed minutes and next earnings - ts2.tech
Pfizer Inc. Is Quietly Rebooting Big Pharma’s Operating System - AD HOC NEWS
Here’s What Analysts Think About Pfizer Inc. (PFE) - Insider Monkey
Here’s what analysts think about Pfizer Inc. (PFE) - MSN
Here's What Analysts Think About Pfizer Inc. (PFE) - Finviz
Pfizer’s Stock Tests Investor Patience as Wall Street Bets on a Post-COVID Rebound - AD HOC NEWS
Pfizer stock slips after hours: what traders are watching ahead of Feb. 3 results - ts2.tech
Pfizer stock today: PFE edges down as Wall Street looks to Feb. 3 results update - ts2.tech
Pfizer Stock Tries To Shake Off Its Covid Hangover: Can A Battered Pharma Giant Turn The Corner? - AD HOC NEWS
Jim Cramer Names His Favorite Dividend Stocks - Yahoo Finance
Pfizer filings spotlight big portfolio shifts as Live Oak slashes stake 92% - ts2.tech
Live Oak Private Wealth LLC Has $449,000 Stake in Pfizer Inc. $PFE - MarketBeat
Ethic Inc. Lowers Holdings in Pfizer Inc. $PFE - MarketBeat
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):